Application of TP53INP2 in diagnosis, treatment and prognosis of dedifferentiated liposarcoma
By analyzing the expression level of TP53INP2 gene in DDLPS, as a biomarker, the recurrence rate and drug resistance in the diagnosis and treatment of dedifferentiated liposarcoma were solved. The combination of TP53INP2 and chemotherapy drugs was used to significantly inhibit the malignant progression of tumor cells. , providing new diagnostic and therapeutic strategies.
Patent Information
- Application Number
- CN202410532502.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-04-29
- Publication Date
- 2024-11-15
AI Technical Summary
The prior art is difficult to effectively diagnose and treat dedifferentiated liposarcoma, especially due to its high recurrence rate and drug resistance, and lacks new molecular targets for drug regulation.
Immunohistochemical technology analyzes the expression level of TP53INP2 gene in tumor tissues as a biomarker to detect the metastasis risk and prognosis of DDLPS, provide new diagnostic and therapeutic targets, and use TP53INP2 promoters in combination with chemotherapeutic drugs to inhibit Growth and metastasis of tumor cells.
TP53INP2 expression is closely related to the malignant progression of DDLPS. High expression suggests a good prognosis, and low expression is related to poor prognosis. Overexpression of TP53INP2 or inhibition of TP53INP2 can significantly inhibit the proliferation and migration of tumor cells, improve chemotherapy sensitivity, and provide new diagnosis and Treatment ideas.
Smart Images

Figure CN118962143A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of gene diagnosis of dedifferentiated liposarcoma, and specifically relates to the application of TP53INP2 gene as a biomarker in the diagnosis and treatment of liposarcoma. Background Art
[0002] Liposarcoma is a malignant tumor composed of fat cells with varying degrees of differentiation and atypia, accounting for about 15-20% of soft tissue sarcomas and one of the most common soft tissue sarcomas in adults. There is currently no clear pathogenic factor for liposarcoma. Gene mutations, chemical reagents, radiation, trauma, and malignant transformation of lipomas may all be involved in the occurrence and development of the tumor. With the rapid development of molecular pathology, the WHO tumor classification also refers to tumor immunohistochemistry, cell and molecular genetics and other characteristics on the basis of tissue morphology. In 2020, WHO mainly divides liposarcoma into the following four types: well-differentiated LPS (WDLPS) or atypical liposarcoma (ALT), dedifferentiated LPS (DDLPS), myxoid LPS (MLPS), and pleomorphic LPS (PLPS). There are great differences in molecular characteristics, clinical manifestations, degree of malignancy and prognosis among various types of liposarcoma. WDLPS is a non-metastatic low-grade lipoma-like tumor with a tendency to local recurrence. It is mainly composed of mature adipocytes of varying sizes and accompanied by nuclear atypia. It is the most common subtype, accounting for about 40-45% of liposarcoma. DDLPS is a highly malignant tumor composed of two components: a poorly differentiated liposarcoma area and a non-fat-derived sarcoma area that suddenly appears malignant. It accounts for about 15-20% of liposarcoma. It is common in the retroperitoneal cavity and is prone to in situ and metastatic recurrence. Genetic studies have shown that both WDLPS and DDLPS can detect excess ring chromosomes and giant chromosomes, and there is amplification in the chromosome 12q13-15 region, which includes many oncogenes related to tumorigenesis, such as Mouse double minute 2 homolog (MDM2), Cyclin-dependent kinase 4 (CDK4), Tetraspanin-31 (TSPAN31), etc. Among them, the most widely studied is MDM2, which is the E3 ubiquitin ligase of the tumor suppressor factor p53 and is amplified in nearly 100% of WDLPS and DDLPS patients. In addition, CDK4 shows co-amplification with MDM2 in more than 90% of WDLPS and DDLPS patients. Therefore, MDM2 and CDK4 are usually used as representative diagnostic genes. Because WDLPS and DDLPS have certain similarities in genetics, some researchers believe that WDLPS can dedifferentiate and transform into DDLPS, and this dedifferentiation occurs in about 10% of WDLPS. Currently, the main treatment for liposarcoma is still surgical resection.Although different types of liposarcoma are highly heterogeneous, the basic principle of surgical treatment is wide resection. Studies have shown that the amount of residual tumor tissue after surgery is significantly correlated with the recurrence rate. In addition, the location of the tumor is also positively correlated with the recurrence rate. In particular, DDLPS has a higher risk of recurrence, and it is difficult for patients to benefit from expanding the scope of resection. Therefore, the application of methods to expand the scope of surgery still needs further study. For LPS treatment, clinical drugs and preclinical prodrugs under development include the following categories: broad-spectrum cytotoxic drugs, MDM2 inhibitors, CDK4 / 6 inhibitors, tyrosine kinase inhibitors, XPO1 inhibitors, and PD-1 inhibitors based on immune checkpoints. For patients with advanced, unresectable or metastatic liposarcoma, drug treatment can significantly delay tumor progression. Doxorubicin-based single-drug or chemotherapy combined with ifosfamide is the standard treatment for recurrent liposarcoma. In recent years, other types of chemotherapy drugs have also been developed to a certain extent. In 2015, the U.S. Food and Drug Administration (FDA) approved Trabectedin for unresectable or advanced liposarcoma, and in 2016, the FDA approved Eribulin for advanced or metastatic liposarcoma that had previously been treated with anthracycline-containing drugs. Liposarcoma has an insidious onset and is difficult to diagnose clinically. The misdiagnosis rate is high in the early stages, and it is often accompanied by liver and lung metastases in the late stages, resulting in a poor prognosis for patients. Currently, DDLPS is treated with surgery as the main treatment and chemotherapy as the auxiliary treatment, but it is very easy to relapse and develop drug resistance. Therefore, the discovery of new molecular targets for drug regulation remains a key issue that needs to be urgently addressed in the treatment of DDLPS.
[0003] In recent years, many studies have shown that tumor protein p53 induciblenuclear protein 2 (TP53INP2) participates in the differentiation of preadipocytes by inducing autophagy, suggesting that TP53INP2-mediated autophagy may play an important role in the occurrence and development of DDLPS. Clarifying the function and mechanism of TP53INP2 in DDLPS will help discover new tumor markers, which can not only be used for DDLPS prognosis judgment, but also provide new therapeutic targets. Summary of the invention
[0004] In order to achieve the above purpose, the present invention uses immunohistochemistry to analyze the relationship between the expression level of TP53INP2 in tumor tissue and the survival and clinical characteristics of DDLPS patients. The results of clinical sample analysis showed that the expression of TP53INP2 gradually decreased with the malignant progression of DDLPS; low expression of TP53INP2 was significantly correlated with the poor prognosis of patients, and the overall survival rate and recurrence-free survival rate of patients with low expression of TP53INP2 were significantly lower than those of patients with high expression; the expression level of TP53INP2 in recurrent tumor tissue was also significantly lower than that in primary tumor tissue. Therefore, it is confirmed that TP53INP2 is a key molecule that negatively regulates the malignant progression of DDLPS, and high expression of TP53INP2 in DDLPS patients indicates a good prognosis.
[0005] In a first aspect, the present invention provides a use of a TP53INP2 gene, mRNA, cDNA, or protein or a detection reagent thereof, (a) as a marker for detecting the risk of metastasis of DDLPS; and / or (b) as a marker for determining the prognosis and survival of DDLPS patients; and / or (c) for preparing a diagnostic reagent or kit for detecting the risk of metastasis of DDLPS; and / or (d) for preparing a diagnostic reagent or kit for determining the prognosis and survival of DDLPS patients.
[0006] In another preferred embodiment, the diagnostic reagent includes antibodies, primers, probes, sequencing libraries, nucleic acid chips (such as DNA chips) or protein chips.
[0007] In another preferred embodiment, the protein includes a full-length protein or a protein fragment.
[0008] In another preferred embodiment, the TP53INP2 gene, mRNA, cDNA, or protein is derived from humans, more preferably, from patients diagnosed with DDLPS.
[0009] In another preferred embodiment, the accession number of the TP53INP2 gene is 58476, also known as DOR.
[0010] In another preferred example, the accession number of the TP53INP2 mRNA is NM_001329431.2.
[0011] In another preferred example, the accession number of the TP53INP2 protein is NP_001316360.1.
[0012] In another preferred embodiment, the detection is tissue sample detection.
[0013] In another preferred embodiment, the detection includes immunohistochemistry, immunoblotting and fluorescence quantitative PCR detection.
[0014] In another preferred embodiment, the detection is to measure DDLPS tissue or general lipoma tissue samples.
[0015] In another preferred embodiment, the detection reagent includes a TP53INP2-specific antibody, a TP53INP2-specific binding molecule, a specific amplification primer, a probe or a chip.
[0016] In another preferred embodiment, the TP53INP2 protein or its specific antibody or specific binding molecule is coupled to or carries a detectable label.
[0017] In another preferred embodiment, the detectable label is selected from the following group: a chromophore, a chemiluminescent group, a fluorophore, an isotope or an enzyme.
[0018] In another preferred embodiment, the TP53INP2-specific antibody is a monoclonal antibody or a polyclonal antibody.
[0019] In a second aspect, the present invention provides a diagnostic kit for (i) detecting the risk of metastasis of DDLPS; and / or (ii) judging the prognosis and survival of DDLPS patients, the kit comprising a container containing a detection reagent for detecting TP53INP2 gene, mRNA, cDNA, or protein; and a label or instructions, the label or instructions indicating that the kit is used for detecting (i) detecting the risk of metastasis of DDLPS; and / or (iii) judging the prognosis and survival of DDLPS patients.
[0020] In another preferred example, the judgment includes prejudgment (prediction).
[0021] In another preferred embodiment, the detection reagent for detecting TP53INP2 gene, mRNA, cDNA, or protein includes: (a) a specific antibody against TP53INP2 protein; and / or (b) a specific primer for specifically amplifying TP53INP2 mRNA or cDNA.
[0022] In another preferred embodiment, the detection is tissue sample detection.
[0023] In another preferred embodiment, the label or instructions state the following: (a) When the TP53INP2 expression level E1 in the DDLPS cells or tissues of the test subject is lower than the TP53INP2 expression level E2 in general fat cells or tissues, it indicates that the risk of cancer cell metastasis in the test subject is higher than that of the general population; (b) When the TP53INP2 expression level E1 in the DDLPS cells or tissues of the test subject is lower than the TP53INP2 expression level E2 in general fat cells or tissues, it indicates that the probability of poor prognosis and shortened survival of the test subject is higher than that of the general population; wherein, the E2 is the expression level of TP53INP2 in general fat cells or tissues of the general population.
[0024] In a third aspect, the present invention provides a method for (i) detecting the risk of metastasis of DDLPS; and / or (ii) determining the prognosis and survival of a DDLPS patient, the method being used for a non-disease diagnosis and treatment method, the method comprising: a) providing a test sample from a subject; b) detecting the expression amount E1 of TP53INP2 protein in the test sample; and c) comparing the expression amount of TP53INP2 protein determined in step b) with the control. Wherein compared with the control, the expression amount of TP53INP2 protein in the sample is lower than the reference value, indicating that the probability of tumor metastasis risk in the subject is higher than that in the general population (control group population); and / or the expression amount of TP53INP2 protein is higher than the reference value, indicating that the probability of cancer cell metastasis risk in the subject is lower than that in the general population (control group population); and / or compared with the control, the expression amount of TP53INP2 protein in the sample is higher than the reference value, indicating that the probability of poor prognosis and shortened survival of the subject is lower than that in the general population (control group population); and / or the expression amount of TP53INP2HTR1A protein is lower than the reference value, indicating that the probability of poor prognosis and shortened survival of the subject is higher than that in the general population (control group population).
[0025] In another preferred embodiment, the subject is a human or non-human mammal.
[0026] In a fourth aspect, the present invention provides a method for determining a treatment regimen, comprising: a) providing a test sample from a subject; b) detecting the expression level of TP53INP2 protein in the test sample; and c) determining a treatment regimen based on the expression level of TP53INP2 protein in the sample. The treatment regimen includes TP53INP2 promoter therapy, TP53INP2 promoter and chemotherapeutic agent (chemotherapeutic drug) (eg, doxorubicin and ifosfamide combined therapy).
[0027] In a fifth aspect, the present invention provides a drug for promoting the expression of the TP53INP2 gene or its protein, including a use for preparing a compound, a composition or a preparation, characterized in that the compound, composition or preparation is used for (a) inhibiting the growth or proliferation of DDLPS cells; and / or (b) inhibiting the metastasis of DDLPS cells; and / or (c) preventing and / or treating DDLPS; and / or (d) increasing the sensitivity of DDLPS cells to chemotherapeutic agents.
[0028] The technical effects of the present invention are
[0029] There are significant differences in the expression of TP53INP2 in DDLPS cell lines of the same origin but different degrees of malignancy. It is low in cell lines with high malignancy and high in cell lines with low malignancy. Moreover, TP53INP2 expression is closely related to the poor prognosis of dedifferentiated liposarcoma. Functional validation results showed that overexpression of TP53INP2 in DDLPS cell line SW872-S cells can significantly inhibit cell proliferation, migration, stemness and dedifferentiation ability. However, interference with TP53INP2 in SW872 cells has the opposite effect. These results confirm that TP53INP2 has an anti-cancer effect. We collected and investigated the expression of TP53INP2 in tumor samples from 79 DDLPS patients and found that the expression of TP53INP2 gradually decreased with the progression of tumor malignancy; low expression of TP53INP2 was significantly associated with poor prognosis of patients, and the overall survival rate and recurrence-free survival rate of patients with low TP53INP2 expression were significantly lower than those of patients with high expression. In addition, compared with the primary tumor, the expression of TP53INP2 also decreased in highly malignant recurrent tumors. In summary, the present invention confirms that TP53INP2 is a key molecule that negatively regulates the malignant progression of DDLPS, and low expression of TP53INP2 is significantly correlated with poor prognosis of patients. Therefore, the discovery of TP53INP2 as a biomarker is helpful for the diagnosis and drug treatment of DDLPS, and provides new ideas for clinical treatment strategies. DETAILED DESCRIPTION
[0030] The present invention can be better understood according to the following examples. However, it is easy for those skilled in the art to understand that the contents described in the implementation cases are only used to illustrate and explain the present invention, and are not used to limit the present invention described in detail in the claims. Unless otherwise specified, the reagents, methods and equipment used in the present invention are conventional methods unless otherwise specified, and the test materials used can be obtained from commercial companies unless otherwise specified.
[0031] Example 1
[0032] Immunohistochemistry
[0033] The steps for immunohistochemical staining of tissue paraffin sections are as follows:
[0034] Dewaxing and hydration of paraffin sections: Bake the paraffin sections in a 55°C oven for 1 hour. Soak the baked sections in xylene 3 times, 10 minutes each time;
[0035] Then soak in anhydrous ethanol for 3 times, 10 min each time;
[0036] Then soak in 75% and 50% ethanol solutions three times, each time for 10 minutes;
[0037] Finally, soak in double distilled water for 10 min.
[0038] (1) Antigen repair: Dilute 50× sodium citrate antigen repair solution to 1× with double distilled water. Pour the diluted antigen repair solution into a pressure cooker. Then put the slices into the pressure cooker and boil them under high pressure for 2 min. After the pressure cooker cools to room temperature, take out the slices and wash them twice in double distilled water for 3 min each time.
[0039] After wiping off the water around the slices, add an appropriate amount of 3% hydrogen peroxide solution, and keep it in the dark for 10 minutes. Then wash the slices with PBST (PBS containing 0.05% Triton X-100) for 3 times, each time for 3 minutes.
[0040] (2) Blocking: Circle the tissue location with a histochemical pen, add 3% goat serum (diluted with PBS) on the sliced tissue, and block at room temperature for 1 hour.
[0041] (3) Incubation with primary antibody: shake off the blocking solution, place the sections in a humidified chamber, add an appropriate amount of primary antibody solution diluted with blocking solution onto the sections, and incubate at 4°C overnight.
[0042] The next day, the sections were washed three times with PBST, each time for 3 min.
[0043] (4) Incubation with secondary antibody: Add appropriate amount of universal secondary antibody for mouse and rabbit to the tissue and incubate at room temperature for 30 min.
[0044] Wash sections three times with PBST, 3 min each time.
[0045] (5) Color development: Wipe off the water around the slice and place it on a piece of white paper, then add an appropriate amount of DAB color developing solution (C:B=50:1).
[0046] The color development time is determined according to the specific protein expression and experimental requirements.
[0047] After color development, place the slide in double distilled water to wash away the color development solution.
[0048] (6) Hematoxylin restaining: Add an appropriate amount of hematoxylin staining solution onto the sliced tissue. After 15-60 seconds, place the slice in double distilled water and wash away the hematoxylin staining solution.
[0049] (7) Dehydration: Soak the sections in 50%, 75%, and 100% ethanol twice each for 5 min each time, and finally soak them in xylene three times for 5 min each time.
[0050] (8) Sealing: Remove the slices from xylene, dry them in a fume hood, add a drop of neutral gum, seal them with a coverslip, and finally observe and photograph them under a microscope.
[0051] Example 2
[0052] Plasmid transformation and extraction
[0053] 1. Plasmid Transformation
[0054] Take 50 μL of competent bacteria (DH5α) and put it on ice to thaw and revive, add an appropriate amount of plasmid (10-100 ng), flick the EP tube to mix, and let it stand on ice for 30 minutes. Then place the competent bacteria in a 42°C water bath for heat shock for 90 seconds, and immediately put it back on ice and let it stand for 2 minutes.
[0055] Then, add 500 μL of LB medium without antibiotics to the competent bacteria and shake on a 37°C constant temperature shaker for 60 min. After the end, place the competent bacteria in a centrifuge and centrifuge at 6000 rpm for 1 min. Discard 450 μL of the supernatant and resuspend the bacteria with the remaining 100 μL of medium. Evenly spread it on an LB solid plate containing the antibiotic corresponding to the plasmid, and invert the plate in a 37°C constant temperature incubator for overnight culture.
[0056] 2. Plasmid Extraction
[0057] Add the preserved bacterial solution to LB medium containing antibiotics, usually 15 mL of medium plus 500 μL of bacterial solution, and place on a 37°C constant temperature shaker for 12-16 hours. Perform plasmid extraction according to the instructions of the endotoxin-free plasmid extraction kit.
[0058] Centrifuge the amplified bacterial solution at 13000rpm for 10min, discard the supernatant medium, resuspend the bacterial precipitate with 500μL Buffer P1, transfer the bacterial suspension to a 2mL EP tube after pipetting and mixing, then add 500μL Buffer P2, mix by inverting and place at room temperature for 5min, then add 500μL Buffer P3, and immediately mix by inverting several times. At this time, a white flocculent precipitate appears, and place at room temperature for 5min. Centrifuge at 13000rpm for 10min, take the supernatant and add it to the endotoxin removal filter column, centrifuge at 13000rpm for 1min twice, collect the filtered liquid in another 2mL EP tube, add 450μL isopropanol, and mix by inverting.
[0059] Add 200μL Buffer PW to the adsorption column, centrifuge at 13000rpm for 2min to complete column balance, discard the filtered liquid, add the filtrate mixed with isopropanol to the adsorption column three times, centrifuge at 13000rpm for 1min each time, and discard the filtrate. Transfer the adsorption column to a 1.5mL EP tube in the clean bench, add 50μL EB preheated to 55℃ for elution, centrifuge at 13000rpm for 2min, and collect the eluted liquid as the extracted plasmid solution. Quantify the plasmid solution and store it in a -20℃ refrigerator.
[0060] Example 3
[0061] Cell culture
[0062] Liposarcoma cells SW872 and SW872-S were cultured in DMEM medium containing 10% FBS and 100,000 U / L of penicillin-streptomycin. The cultured cells were placed in a cell culture incubator containing 5% CO2 and 37°C, digested with trypsin every 2 days, centrifuged at 180g for 5 minutes, and the cells were passaged at a ratio of 1:2.
[0063] Example 4
[0064] Cell transfection
[0065] Evenly spread the cells in a 6-well plate, adhere to the wall overnight, and transfect at a cell density of about 60-70%. Take two 1.5mL EP tubes without nuclease in the clean bench, add 200μL Opti-MEM medium to each, add 2μg plasmid and 4μL P3000 to one tube, flick to mix and let stand for 5 minutes. Add 4μL Lipo3000 to the other tube. After standing, mix the two tubes of liquid together, flick to mix, and let stand for 15-20 minutes. Finally, slowly add the liquid to the cell culture well, change the liquid after 6 hours, and continue to culture for 24-48 hours.
[0066] Example 5
[0067] siRNA interference
[0068] The cells were evenly plated in a 6-well plate and allowed to adhere overnight. The cell density was about 60-70% for interference. 200 μL Opti-MEM medium and 6 μL RNAiMAX and 25 pmol of siRNA were gently flicked to mix and then allowed to stand for 15-20 minutes.
[0069] At the same time, the culture medium in the cells was replaced with DMEM culture medium containing 3% FBS, and the mixed solution after incubation was slowly dripped into the cell culture wells. After 6 hours, it was replaced with DMEM culture medium containing 10% FBS and double antibodies and cultured for another 24-48 hours.
[0070] Example 6
[0071] Western blotting
[0072] 1. Protein Extraction
[0073] Trypsin digestion: collect the pretreated cells into EP tubes, centrifuge at 6000rpm for 1min at 4°C, discard the supernatant, wash the cell pellet once with pre-cooled phosphate buffer, discard the supernatant, add appropriate amount of Western and IP cell lysis buffer containing 1mM PMSF according to the cell amount, mix well by pipetting and briefly vortex the cell pellet, and then lyse on ice for 35min.
[0074] After lysis, place the EP tube in a pre-cooled high-speed centrifuge and centrifuge at 4°C, 130,000 rpm for 10 minutes. Transfer the supernatant after centrifugation to a new EP tube, which is the protein sample.
[0075] 2. Protein Quantification
[0076] Quantify the protein sample according to the instructions of the BCA protein quantification kit. Gradually dilute the BSA standard in a centrifuge tube, with a volume of 25 μL per tube. Add 24 μL of double distilled water and 1 μL of protein sample to the sample tube. Immediately add 200 μL of BCA mixture (A: B = 50: 1), vortex briefly to mix, and place in a 37°C constant temperature incubator for reaction for 30 minutes.
[0077] After the reaction is completed, the mixed solution in the EP tube is transferred to the ELISA well, and the absorbance is detected at a wavelength of 570nm using an ELISA reader. The standard curve is fitted according to the concentration and absorbance of the standard, and the sample concentration is calculated by inserting the absorbance value of the sample.
[0078] 3. Protein denaturation
[0079] Dilute the protein sample to the same concentration using Western and IP cell lysate and 6× loading buffer, usually 2 μg / μL.
[0080] The prepared protein sample was heated in boiling water for 5 minutes and then briefly centrifuged to avoid loss of sample residual liquid on the EP tube cap and tube wall. Finally, the sample was placed in a -20℃ refrigerator for use.
[0081] 4. Electrophoresis
[0082] Prepare SDS-PAGE gel of appropriate concentration according to the molecular weight of the target protein, fix the gel in the electrophoresis tank, add Running buffer, remove the comb teeth and prepare for sample loading.
[0083] After the sample was taken out of the -20°C refrigerator and thawed, it was vortexed and briefly centrifuged, and 20-30 μg of protein sample was added to each well.
[0084] Electrophoresis was performed under constant voltage conditions, with the compression gel at 60 V, and the voltage was adjusted to 100-120 V after entering the separation gel. The electrophoresis was terminated when the desired target protein was completely separated.
[0085] 5. Transfer
[0086] Pre-prepare Trans buffer and chill on ice.
[0087] After electrophoresis, the proteins on the gel were transferred to the PVDF membrane using the wet transfer method. That is, the gel was first placed on the sponge and filter paper on the black side of the transfer clamp, and the PVDF membrane activated with methanol was placed on the surface of the gel. The bubbles between the membrane and the gel were removed, and then a layer of filter paper and sponge were applied. The transfer clamp was closed and the transfer was started in the transfer tank. The conditions were ice bath, constant current of 350mA, and 90min.
[0088] 6. Blocking and incubation with antibodies
[0089] After the transfer, place the membrane in a 3% BSA or 5% skimmed milk powder solution diluted in washing buffer, shake it slowly on a flat shaker, and block it at room temperature for 90 minutes.
[0090] The PVDF membrane was cut according to the molecular weight of the pre-stained marker and the molecular weight of the desired target protein, placed in a film pocket, and diluted primary antibody solution was added. After sealing, the membrane was incubated overnight in a 4°C rotating oven.
[0091] On the next day, after removing the primary antibody solution, the strips were rinsed three times with Washing buffer on a shaker, each time for 10 min.
[0092] After rinsing, place the strips into a film pocket, add the diluted secondary antibody solution according to the primary antibody species, seal it, and incubate it in a room temperature oven for 90 minutes.
[0093] After incubation, the secondary antibody solution was removed and the strips were rinsed three times with Washing buffer on a shaker for 10 min each time.
[0094] 7. Development
[0095] Place the rinsed strips into an X-ray cassette covered with a layer of plastic wrap, then drop the prepared ECL luminescent liquid evenly on the strips, and finally cover them with another layer of plastic wrap.
[0096] Press the X-ray film onto the membrane, quickly close the cassette, and after leaving it for an appropriate time based on protein expression and luminescence intensity, take out the film and place it in a film processor for development.
[0097] After the developed film is washed and dried, it is placed on a scanner for scanning and imaging for subsequent further data analysis and processing.
[0098] Example 7
[0099] RNA extraction
[0100] 1. RNA Extraction and Quantification
[0101] The pretreated cells in the 6-well plate were rinsed twice with PBS to remove the residual culture medium, 1 mL of Trizol was added to each well, and the mixture was placed on ice for 5 min. The Trizol and cells were mixed by pipetting and then transferred to the 1.5 mL EP tube containing the nuclease.
[0102] Add 200 μL of chloroform to each tube, shake vigorously for 20 seconds, let stand at room temperature for 15 minutes, and then centrifuge at 12000g for 15 minutes at 4°C. Carefully aspirate the upper aqueous phase and place it in another new 1.5mL EP tube for denuclease, add an equal volume of isopropanol, mix by inverting, let stand at room temperature for 10 minutes, and then centrifuge at 12000g for 10 minutes.
[0103] Then discard the supernatant and wash the precipitate twice with 75% ethanol, centrifuging at 12000g for 10 min each time. After discarding the supernatant, open the tube cap and blow dry the remaining liquid in a fume hood until the RNA becomes transparent, which takes about 25-30 min.
[0104] Add an appropriate amount of RNase-free water to the dried RNA to dissolve the precipitate, and finally use a micro-UV-visible spectrophotometer to detect the RNA concentration.
[0105] 2. Reverse Transcription
[0106] Prepare 20 μL reverse transcription reaction system, including 1 μg RNA, 4 μL RT Buffer, 2 μL dNTP, 1 μL OligodT, 0.25 μL RT ACE, 0.25 μL RI, and make up to 20 μL with RNase-free water.
[0107] Then put it into a common PCR instrument for reverse transcription.
[0108] The reaction conditions were: 42°C for 20 min, 99°C for 5 min, and finally the mixture was cooled to 4°C and taken out and stored at -20°C.
[0109] Example 8
[0110] Real-time quantitative PCR
[0111] Prepare 10 μL system for real-time quantitative PCR reaction, including 5 μL iQTM Green Supermix, 1 μL cDNA, 0.5 μL each of forward and reverse primers, and 3 μL DEPC water.
[0112] The above mixed solution was added to the PCR detection plate, sealed with a PCR membrane and centrifuged briefly, and the prepared PCR plate was placed in a Bio-Rad CFX96 real-time fluorescence quantitative PCR instrument for amplification.
[0113] The reaction conditions were: 1 cycle of pre-denaturation at 95°C for 2 min, 40 cycles of denaturation at 95°C for 10 s and annealing and extension at 60°C for 30 s. Dissolution was performed with a program of 65°C for 5 s and 95°C for 0.5 s for a total of 35 cycles. The results were normalized using the number of cycles of Actin as a reference gene.
[0114] Example 9
[0115] MTT cell proliferation
[0116] Cells growing in logarithmic phase or transfected cells were evenly plated in a 96-well plate, 3000 cells / 200 μL culture medium / well, with three replicate wells in each group, and allowed to adhere overnight.
[0117] After 24, 48 or 72 h, 20 μL of 5 mg / mL MTT solution was added to each well and the cells were placed in a cell culture incubator and cultured for 4 h.
[0118] After the time is up, centrifuge the plate at 2000rpm for 5min. Use a 1mL syringe to suck out the supernatant liquid, leaving the formazan generated by the reaction, add 200μL DMSO to each well to dissolve the formazan, place the plate on a flatbed shaker and shake for 10min. After the end, use an ELISA reader to detect the absorbance value at 570nm.
[0119] The relative viability of cells was calculated using the negative control wells.
[0120] Example 10
[0121] Scratch test
[0122] The cells were evenly seeded into 6-well plates and continued to be cultured after transfection. When the cells grew to nearly 100% density, three lines were made in the wells with the tip of a micropipette and the remaining cell debris was washed away with PBS.
[0123] Pictures were taken at the same position using a microscope at 0h, 12h, 24h, and 36h, and cell migration was analyzed using Image J software.
[0124] Embodiment 11
[0125] Oil red staining
[0126] The cells were evenly seeded into a 24-well plate and cultured for 48 hours after transfection. The supernatant of the culture medium was aspirated, the cells were washed twice with PBS, and 200 μL of paraformaldehyde was added to fix the cells at room temperature for 30 minutes. The fixative was discarded, and the cells were washed twice with PBS and then the PBS was discarded.
[0127] Add 200 μL of Oil Red working solution to each well (Oil Red mother solution: weigh 0.5 g of Oil Red powder and dissolve it in 100 mL of isopropanol. After it is fully dissolved, store it in a refrigerator at 4°C. Mix the Oil Red mother solution and double distilled water in a ratio of 3:2 to obtain the Oil Red working solution).
[0128] Stain at room temperature for 30 minutes. Discard the staining solution, wash with double distilled water 5 times, and observe under a microscope.
[0129] Example 12
[0130] Statistical methods
[0131] The results are expressed as mean±SEM. One-way analysis of variance (ANOVA) was used first. If there were differences, the comparison between the two groups was tested by Student's-t test, and the comparison between more than two groups was tested by Dunnett's test. *P<0.05, **P<0.01, ***P<0.001.
[0132] Effect example 1 TP53INP2 expression level is negatively correlated with the malignant progression of DDLPS
[0133] Since DDLPS has a higher metastasis and recurrence rate than other subtypes and poor sensitivity to chemotherapy drugs, we collected clinical samples from 79 DDLPS patients from 1985 to 2018, prepared them into tissue chips, and detected the expression of TP53INP2 in liposarcoma tissues by immunohistochemistry. Based on the patient information, the overall survival (OS) and recurrence-free survival (RFS) of all patients were statistically analyzed with tumor location. Figure 1 As shown in Figure 2, the results showed that in DDLPS, the expression of TP53INP2 gradually decreased with the increase of tumor grade. Figure 2 As shown in A and B, compared with DDLPS patients with high TP53INP2 expression, patients with low TP53INP2 expression had shorter OS and RFS. Figure 2As shown in C and D, for patients with tumors in the retroperitoneum or intraperitoneal cavity, the OS and RFS of DDLPS patients with low TP53INP2 expression were significantly lower than those of patients with high TP53INP2 expression. Due to the small number of samples of patients with tumors in the limbs, there was no significant difference in OS and RFS between patients with low TP53INP2 expression in the retroperitoneum or intraperitoneal cavity and those with tumors in the limbs. The soft tissue sarcoma samples were analyzed through the website http: / / www.cbioportal.org / , as shown in Figure 3 As shown in the results, TP53INP2 was found to be significantly negatively correlated with multiple soft tissue sarcoma cancer-promoting markers (such as CDK4, MKI67 and MDM2) at the mRNA level, suggesting that TP53INP2 may inhibit the malignant progression of soft tissue sarcoma.
[0134] Effect Example 2: TP53INP2 is expressed at a lower level in recurrent tumors compared to primary tumors
[0135] The expression of TP53INP2 in tumor tissues of multiple patients before and after recurrence was statistically analyzed. Figure 4 As shown, among 8 DDLPS patients, 4 patients had decreased TP53INP2 expression after recurrence; among 4 MLPS patients, all patients had decreased TP53INP2 expression after recurrence; among 3 PLPS patients, 2 patients had decreased TP53INP2 expression after recurrence. Overall, among 15 liposarcoma patients, 10 patients (66.7%) had a decreasing trend of TP53INP2 expression after recurrence, indicating that compared with the primary tumor, TP53INP2 expression is decreased in highly malignant recurrent liposarcoma.
[0136] Effect Example 3 TP53INP2 inhibits the malignancy of DDLPS cells
[0137] In our previous study, we used human liposarcoma cells SW872 to repeatedly implant tumors in nude mice. Figure 5 As shown in A, SW872-S cells were obtained, which were derived from the same source as SW872 cells but were more malignant. Figure 5 As shown in B and C, using this pair of cell lines, we first compared the expression of TP53INP2. Consistent with clinical samples, the mRNA and protein levels of TP53INP2 in highly malignant SW872-S cells were significantly lower than those in less malignant SW872 cells. Figure 6 As shown in A, Flag-NC (empty control plasmid) and Flag-TP53INP2 (overexpression TP53INP2 plasmid) were transfected into SW872-S cells, and the results of the MTT assay to detect cell viability showed that overexpression of TP53INP2 reduced the proliferation ability of liposarcoma cells. Figure 6As shown in B and C, the results of the scratch assay showed that overexpression of TP53INP2 reduced the migration ability of liposarcoma cells. Figure 6 As shown in D, real-time quantitative PCR revealed that overexpression of TP53INP2 could significantly reduce the expression of stemness markers ALDH1, CD133, and NANOG genes in liposarcoma cells. Figure 6 As shown in E, the results of the Oil Red O staining experiment showed that overexpression of TP53INP2 can promote lipid droplet formation. These results show that overexpression of TP53INP2 inhibits the malignant progression of liposarcoma cells. Figure 7 As shown, TP53INP2 was knocked down by siRNA interference in SW872 cells. The above method was used to find that knocking down TP53INP2 promoted liposarcoma cell proliferation (A), migration (B, C), stemness markers ALDH1, CD133, NANOG gene expression (D), and inhibited lipid droplet formation (E). These results support the function of TP53INP2 in inhibiting the malignant progression of liposarcoma cells.
[0138] The above shows and describes the basic principles, main features and advantages of the present invention. Those skilled in the art should understand that the present invention is not limited to the above embodiments, and the above embodiments and descriptions are only for explaining the principles of the present invention. The present invention may be subject to various changes and improvements without departing from the spirit and scope of the present invention, and these changes and improvements fall within the scope of the present invention to be protected. BRIEF DESCRIPTION OF THE DRAWINGS
[0139] Figure 1 TP53INP2 expression levels are negatively correlated with the malignant progression of DDLPS Clinical samples of 79 patients with DDLPS in the T1-T4 stage from 1985 to 2018 were collected and prepared into tissue microarrays, and the expression of TP53INP2 in liposarcoma tissues was detected by immunohistochemistry. A. Representative results of immunohistochemical detection of TP53INP2 expression in liposarcoma tissues. Pathological numbers are below the IHC graph. Scale bar, 50 μm. B. Statistical results of immunohistochemical detection of TP53INP2 expression levels. The IHC intensity of TP53INP2 in tumor tissues was analyzed by Image j, and the data are shown as mean ± SEM. **P < 0.01.
[0140] Figure 2 Correlation between TP53INP2 expression level and prognosis of DDLPS According to the patient information, the overall survival (OS) and recurrence-free survival (RFS) of all patients were correlated with the expression level of TP53INP2 in liposarcoma tissues. AB. Correlation between the expression level of TP53INP2 in liposarcoma tissues and the OS (A) and RFS (B) of patients. CD. Correlation between the expression level of TP53INP2 and the OS (C) and RFS (D) of patients whose tumors were located in the retroperitoneum / intraperitoneum or limbs.
[0141] Figure 3 TP53INP2 gene expression is negatively correlated with multiple soft tissue sarcoma cancer-promoting markers The correlation of TP53INP2 with multiple soft tissue sarcoma cancer-promoting markers A. CDK4, B. MKI67 and C. MDM2 at the mRNA level was analyzed in soft tissue sarcoma samples through the website http: / / www.cbioportal.org / .
[0142] Figure 4 TP53INP2 is expressed at lower levels in recurrent tumors compared with primary tumors Immunohistochemistry was used to count the expression of TP53INP2 in tumor tissues of multiple patients with different types of liposarcoma before and after recurrence.
[0143] Figure 5 The expression level of TP53INP2 in highly malignant SW872-S cells was lower than that in low-malignant SW872 cells. Human liposarcoma cells SW872 were repeatedly implanted in nude mice to obtain SW872-S cells with higher malignancy. A. Schematic diagram of constructing malignant liposarcoma cell lines. B. Comparison of TP53INP2 mRNA levels by real-time quantitative PCR. C. Comparison of TP53INP2 protein levels by western blotting. Data are expressed as mean ± SEM of three independent experiments. *P<0.05.
[0144] Figure 6 Overexpression of TP53INP2 inhibits the malignant progression of liposarcoma cells Flag-NC (empty control plasmid) and Flag-TP53INP2 (overexpression TP53INP2 plasmid) were transfected into SW872-S cells. A. Cell viability was detected by MTT assay. BC. Cell migration ability was detected by scratch assay. B. Representative graphs; C. Statistical results. D. Real-time quantitative PCR was used to detect the expression of stemness markers ALDH1, CD133, and NANOG genes in liposarcoma cells. E. Oil red O staining was used to detect lipid droplet formation. Data are expressed as mean ± SEM of three independent experiments. *P<0.05, **P<0.01, ***P<0.001.
[0145] Figure 7 Knockdown of TP53INP2 promotes the malignant progression of liposarcoma cells TP53INP2 was knocked down by siRNA interference in SW872 cells. A. Cell viability was detected by MTT assay. BC. Cell migration ability was detected by scratch assay. B. Representative graphs; C. Statistical results. D. Real-time quantitative PCR was used to detect the expression of stemness markers ALDH1, CD133, and NANOG genes in liposarcoma cells. E. Oil red O staining was used to detect lipid droplet formation. Data are expressed as mean ± SEM of three independent experiments. *P<0.05, **P<0.01, ***P<0.001.
Claims
1. A biomarker for diagnosis, prognosis and treatment, characterized in that: The TP53INP2 protein has the use of inhibiting the growth or proliferation of dedifferentiated liposarcoma (DDLPS) cells; and / or inhibiting the metastasis of DDLPS cells; and / or being used in a composition for treating DDLPS.
2. The protein according to claim 1, characterized in that Provided is a method for (i) detecting the risk of metastasis of DDLPS; and / or (ii) judging the prognosis and survival period of a DDLPS patient, wherein the method is used for non-disease diagnosis and treatment methods.
3. The protein according to claim 1, characterized in that Used to prepare a diagnostic kit for (i) detecting the risk of metastasis of DDLPS; and / or (ii) judging the prognosis and survival period of DDLPS patients.
4. The protein according to claim 1, characterized in that Treatment options are provided, either alone or in combination, and include the following steps: a) providing a test sample from a subject; b) detecting the expression level of TP53INP2 protein in the test sample; c) determining a single medication treatment regimen based on the expression level of TP53INP2 protein in the sample; d) determining a combination therapy regimen based on the expression level of TP53INP2 protein in the sample.
Citation Information
Patent Citations
P53 biomarkers
CN102066937A
Application of GPS2 gene in preparation of drugs for prognosis, diagnosis or prevention and treatment of soft tissue tumor
CN106075468A
Use of anti-PD-1 antibodies in treatment of malignancies
CN115066260A
Cited By
Application of circular non-coding RNA-circSATB2015 in diagnosis or treatment of vascular proliferative diseases
CN119552957A
Bionanomaterial for treating retroperitoneal liposarcoma
CN120859971A
